| diabetes type 2 | versus placebo or control No demonstrated result for efficacy olmesartan inferior to placebo in terms of CV death in ROADMAP, 2010 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ROADMAP, 2010 | olmesartan vs placebo | onset of microalbuminuria 0.77 [0.63; 0.94] | CV death 4.96 [1.44; 17.12] | all cause death 1.72 [0.91; 3.24] non fatal stroke 1.74 [0.73; 4.13] non fatal MI 0.65 [0.35; 1.19] CV events 0.88 [0.63; 1.23] | | ORIENT | olmesartan vs placebo | | | all cause death 0.96 [0.52; 1.75] CV death 3.36 [0.93; 12.07] non fatal stroke 0.73 [0.30; 1.79] non fatal MI 0.43 [0.11; 1.65] |
| Trial | Treatments | Patients | Method |
|---|
| ROADMAP, 2010 | olmesartan at 40 mg/day (n=2232) vs. placebo (n=2215) | patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | double-blind Parallel groups Sample size: 2232/2215 Primary endpoint: microalbuminuria FU duration: 3.2 y | | ORIENT | olmesartan (n=282) vs. placebo (n=284) | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus | double-blind Parallel groups Sample size: 282/284 Primary endpoint: FU duration: |
|
| miscellaneous | versus placebo or control No demonstrated result for efficacy olmesartan inferior to placebo in terms of CV death in ROADMAP, 2010 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ROADMAP, 2010 | olmesartan vs placebo | onset of microalbuminuria 0.77 [0.63; 0.94] | CV death 4.96 [1.44; 17.12] | all cause death 1.72 [0.91; 3.24] non fatal stroke 1.74 [0.73; 4.13] non fatal MI 0.65 [0.35; 1.19] CV events 0.88 [0.63; 1.23] | | ORIENT | olmesartan vs placebo | | | all cause death 0.96 [0.52; 1.75] CV death 3.36 [0.93; 12.07] non fatal stroke 0.73 [0.30; 1.79] non fatal MI 0.43 [0.11; 1.65] |
| Trial | Treatments | Patients | Method |
|---|
| ROADMAP, 2010 | olmesartan at 40 mg/day (n=2232) vs. placebo (n=2215) | patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | double-blind Parallel groups Sample size: 2232/2215 Primary endpoint: microalbuminuria FU duration: 3.2 y | | ORIENT | olmesartan (n=282) vs. placebo (n=284) | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus | double-blind Parallel groups Sample size: 282/284 Primary endpoint: FU duration: |
|
